
    
      To investigate the efficacy (complete response [CR] + partial response [PR]) of forodesine in
      treating subjects with CLL who have failed at least one prior treatment regimen or who are
      treatment na√Øve but are either elderly, have poor performance status or are otherwise
      predicted not to tolerate cytotoxic chemotherapy.
    
  